Company: CMND
Filing Date: 2025-09-15
Form Type: POS AM
Source: 0001213900-25-087398
Chunk: 2

Company: Clearmind Medicine Inc.
Filing Date: 2025-09-15
Form: POS AM
Chunk 2
---
 Amendment No. 1 was declared effective by the Securities
and Exchange Commission on March 22, 2024.

On July 23, 2024, the Registrant
filed Post-Effective Amendment No. 2 to update and supplement information contained in the Registration Statement, and also to include
updated financial information. Post-Effective Amendment No. 2 was declared effective by the Securities and Exchange Commission on July
30, 2024.

On September 24, 2024, the Registrant
filed Post-Effective Amendment No. 3 to update and supplement information contained in the Registration Statement, and also to include
updated financial information. Post-Effective Amendment No. 3 was declared effective by the Securities and Exchange Commission on September
30, 2024.

On January 22, 2025, the Registrant filed Post-Effective
Amendment No. 4 to update and supplement information contained in the Registration Statement, and also to include updated financial information.
Post-Effective Amendment No. 4 was declared effective by the Securities and Exchange Commission on February 18, 2025.

On March 13, 2025, the Registrant filed Post-Effective
Amendment No. 5 to update and supplement information contained in the Registration Statement, and also to include updated financial information.
Post-Effective Amendment No. 5 was declared effective by the Securities and Exchange Commission on March 17, 2025.

On June 12, 2025, the Registrant filed Post-Effective
Amendment No. 6 to update and supplement information contained in the Registration Statement, and also to include updated financial information.
Post-Effective Amendment No. 6 was declared effective by the Securities and Exchange Commission on June 18, 2025.

This Post-Effective Amendment No. 7 is being
filed by the Registrant to update and supplement information contained in the Registration Statement, and also to include updated financial
information.

No additional securities are being registered
under this Post-Effective Amendment No. 7. This Post-Effective Amendment No. 7 concerns only the sale of the Common Shares by the Selling
Shareholders from time to time.

All filing fees payable in connection
with the registration of these securities were previously paid in connection with the initial filing of the Registration Statement.

The information in this prospectus is not complete and may be changed. The selling shareholders may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective